PCNA Antibody - BSA Free

Western Blot: PCNA Antibody [NB100-456]

Western Blot: PCNA Antibody [NB100-456] - A431 whole cell lysates

Western Blot: PCNA Antibody [NB100-456]

Western Blot: PCNA Antibody [NB100-456] - Analysis using the Biotin conjugate of NB100-456. Detection ofHeLa (50, 15, and 5 ug). Antibody used at 1.0 ug/ml. Detection: Streptavidin-HRP and chemiluminescence with an exposure time of 3 seconds.

Immunoprecipitation: PCNA Antibody [NB100-456]

Immunoprecipitation: PCNA Antibody [NB100-456] - Detection of human PCNA by western blot and immunoprecipitation. Samples: A. Whole cell lysate (WCL) from A-431 cells. B. WCL (500 ug for IP; 30 ug for WCL lane) from MDA-MB-468 cells. Antibodies: A. Affinity purified rabbit anti-PCNA antibody NB100-456 used at the indicated concentrations for WB. B. PCNA was immunoprecipitated using another a mouse monoclonal antibody to PCNA (mAb). Control mock IP was performed using normal mouse IgG (M-IgG) and normal rabbit IgG (R-IgG). immunoprecipitatesd PCNA was blotted using NB100-456 (1 ug/ml). Detection: Chemiluminescence with an exposure time of 2 minutes (A) or 5 seconds (B).

Western Blot: PCNA Antibody - BSA Free [NB100-456] -

MLE and nCGA reduced the expression of proliferation-related proteins in diabetic cultured VSMCs. (A) The levels of PI3K, p-Akt, and PCNA in OH-treated A7r5 cells were notably increased under OH conditions and notably decreased after treatment with nCGA (40 and 120 μM). (B) In OH-stimulated A7r5 cells, the levels of Ras and p-ERK were increased, and OH-induced upregulation was nullified by nCGA. The quantitative data are presented as the mean +/- SD from a minimum of three independent experiments. # p < 0.05 as compared to the C (control). * p < 0.05 as compared to the OH group. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35893859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.